David L. McKinzie

David L. McKinzie publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where David L. McKinzie sits on this spectrum.

David L. McKinzie D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where David L. McKinzie sits on this spectrum.

Best Publications

• Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

  Anantha Shekhar;William Z. Potter;Jeffrey Lightfoot;John Lienemann

  604
  Citations

• Diverse psychotomimetics act through a common signaling pathway.

  Per Svenningsson;Eleni T. Tzavara;Robert Carruthers;Ilan Rachleff

  367
  Citations

• 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine : a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism

  Donald R. Gehlert;Andrea Cippitelli;Annika Thorsell;Anh Dzung Lê

  349
  Citations

• Cholinergic dilation of cerebral blood vessels is abolished in M 5 muscarinic acetylcholine receptor knockout mice

  Masahisa Yamada;Kathryn G. Lamping;Alokesh Duttaroy;Weilie Zhang

  347
  Citations

• Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

  Frank P. Bymaster;David L. McKinzie;Christian C. Felder;Jürgen Wess

  304
  Citations

• Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats.

  Zachary A. Rodd-Henricks;David L. McKinzie;Robert S. Crile;James M. Murphy

  293
  Citations

• M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.

  Eleni T. Tzavara;Frank P. Bymaster;Richard J. Davis;Mark R. Wade

  260
  Citations

• Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

  W. Y. Chan;D. L. McKinzie;S. Bose;S. N. Mitchell

  250
  Citations

• Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).

  Michael P. Johnson;David Barda;Thomas C. Britton;Renee Emkey

  246
  Citations

• Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity.

  Frank P. Bymaster;Petra A. Carter;Masahisa Yamada;Jesus Gomeza

  228
  Citations

• Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

  E T Tzavara;F P Bymaster;C C Felder;M Wade

  213
  Citations

• Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

  Bruce J. Kinon;Bruce J. Kinon;Brian A. Millen;Lu Zhang;David L. McKinzie

  209
  Citations

• Cocaine Is Self-Administered into the Shell but Not the Core of the Nucleus Accumbens of Wistar Rats

  Zachary A. Rodd-Henricks;David L. McKinzie;Ting Kai Li;James M. Murphy

  202
  Citations

• Muscarinic mechanisms of antipsychotic atypicality.

  Frank P. Bymaster;Christian C. Felder;Eleni Tzavara;George G. Nomikos

  199
  Citations

• LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.

  Linda M. Rorick-Kehn;Jeffrey M. Witkin;Michael A. Statnick;Elizabeth L. Eberle

  188
  Citations

• In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

  Linda M. Rorick-Kehn;Bryan G. Johnson;Karen M. Knitowski;Craig R. Salhoff

  187
  Citations

• Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

  Katie Leach;Richard E Loiacono;Christian C Felder;David L McKinzie

  178
  Citations

• Role for M5 muscarinic acetylcholine receptors in cocaine addiction.

  Anders Fink-Jensen;Irina Fedorova;Gitta Wörtwein;David P. D. Woldbye

  164
  Citations

• Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)

  Linda M. Rorick-Kehn;Bryan G. Johnson;Jennifer L. Burkey;Rebecca A. Wright

  155
  Citations

• Elucidating the role of muscarinic receptors in psychosis.

  Christian C. Felder;Amy C. Porter;Tiffanie L. Skillman;Lu Zhang

  154
  Citations